| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11239-005-3204-6 |
| P698 | PubMed publication ID | 16205859 |
| P2093 | author name string | Robin L Brey | |
| P2860 | cites work | Thrombosis, abortion, cerebral disease, and the lupus anticoagulant | Q24675412 |
| Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke | Q28167141 | ||
| Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome | Q28196659 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus | Q33329033 | ||
| GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. | Q33329778 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. | Q33342481 | ||
| A family study of the antiphospholipid syndrome associated with other autoimmune diseases | Q33356141 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases | Q33408807 | ||
| Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome | Q33488745 | ||
| Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation | Q33489097 | ||
| Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects | Q33490868 | ||
| A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis | Q33500954 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Antiphospholipid syndrome: multiple mechanisms | Q35775322 | ||
| Beta 2 glycoprotein I--function in health and disease | Q35928646 | ||
| Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies | Q35928725 | ||
| Coronary and valvular syndromes and antiphospholipid antibodies | Q35928744 | ||
| The role of antiphospholipid antibodies in stroke. | Q35966558 | ||
| Antiphospholipid antibodies in patients without systemic lupus erythematosus: neuroradiologic findings | Q36734064 | ||
| Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity | Q39514521 | ||
| Antiphospholipid antibodies in an in vivo thrombosis model in mice | Q40558495 | ||
| beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program | Q40693493 | ||
| Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Västerbotten cohort project | Q40763035 | ||
| Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic 'rheumatic type' valvular heart disease | Q40776802 | ||
| Cerebral venous thrombosis and anticardiolipin antibodies | Q41669380 | ||
| Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus | Q41837002 | ||
| Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype | Q43837381 | ||
| Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo | Q43882937 | ||
| Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: a descriptive study of 139 patients | Q43933330 | ||
| Antiphospholipid antibodies and stroke in young women | Q44168396 | ||
| Using 99mTc HMPAO brain SPECT to evaluate the effects of anticoagulant therapy on regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with brain involvement-a preliminary report | Q44396576 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Anti-cardiolipin antibodies in ischaemic heart disease. | Q46941158 | ||
| MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension | Q48129276 | ||
| Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis | Q48394757 | ||
| High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause | Q48398617 | ||
| Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies | Q48491099 | ||
| The frequency of phospholipid antibodies in an unselected stroke population | Q48494425 | ||
| Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia | Q48537242 | ||
| Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study | Q48657312 | ||
| Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus | Q48793158 | ||
| Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings | Q49226626 | ||
| Anticardiolipin antibodies are an independent risk factor for ischemic stroke. | Q51980287 | ||
| Familial antiphospholipid antibody syndrome: Criteria for disease and evidence for autosomal dominant inheritance | Q57186231 | ||
| Cerebral venous thrombosis | Q68086639 | ||
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor | Q68090535 | ||
| Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease | Q68091809 | ||
| Antiphospholipid antibodies and cerebral ischemia in young people | Q68347645 | ||
| Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. The Antiphospholipid Antibodies in Stroke Study Group | Q68910126 | ||
| Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group | Q70514603 | ||
| MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus | Q71572881 | ||
| Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis | Q71614846 | ||
| Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus | Q71775354 | ||
| Antiphospholipid antibodies lead to increased risk in cardiovascular surgery | Q71949874 | ||
| Anticardiolipin antibodies in an unselected stroke population | Q72402253 | ||
| Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects | Q72433855 | ||
| Clinicopathologic correlations of antiphospholipid antibodies. An autopsy study | Q72450198 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS) | Q73012729 | ||
| Antiphosphatidyl serine antibodies are independently associated with ischemic stroke | Q73114357 | ||
| Familial antiphospholipid syndrome and HLA-DRB gene associations | Q73802412 | ||
| The association of antiphospholipid antibodies with ischaemic stroke and myocardial infarction in young and their correlation: a preliminary study | Q73899371 | ||
| Phospholipid specificity of autoimmune and drug induced lupus anticoagulants; association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease | Q74267102 | ||
| Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients | Q74284472 | ||
| Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study | Q74575122 | ||
| Anticardiolipin antibodies and their associations with cerebrovascular risk factors | Q77398222 | ||
| Beta2-glycoprotein I as a 'cofactor' for anti-phospholipid reactivity with endothelial cells | Q77549919 | ||
| Origin of antiphospholipid antibodies: induction of aPL by viral peptides | Q77549928 | ||
| Detection of cerebral microemboli in APS--introducing a novel investigation method and implications of analogies with carotid artery disease | Q77549943 | ||
| Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides | Q78248010 | ||
| Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results | Q93670714 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 105-12 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Antiphospholipid antibodies in young adults with stroke | |
| P478 | volume | 20 |
| Q37790448 | A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke |
| Q36561992 | Antiphospholipid syndrome: what's new in understanding antiphospholipid antibody-related stroke? |
| Q37374156 | Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. |
| Q35041133 | Congenital cerebral palsy, child sex and parent cardiovascular risk |
| Q35116961 | Epidemiology and etiology of young stroke |
| Q46715633 | Ictus and antiphospholipid syndrome: how much is enough? |
| Q26824314 | Ischemic stroke in young adults: an overview of etiological aspects |
| Q51752530 | Mitral valve prolapse in young healthy individuals. An early index of autoimmunity? |
| Q80335294 | Neurologic manifestations of the antiphospholipid syndrome |
| Q53096115 | Neurological presentations of the antiphospholipid syndrome: three illustrative cases. |
| Q38794847 | Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population? |
| Q37775992 | Screening for coagulation disorders in patients with ischemic stroke |
| Q28084428 | Strokes in young adults: epidemiology and prevention |
| Q45122099 | The pathogenesis of neural injury in animal models of the antiphospholipid syndrome |
Search more.